MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Cahill
Daniel P
DP
Neurosurgical Service, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Codd
Patrick J
PJ
Batchelor
Tracy T
TT
Curry
William T
WT
Louis
David N
DN
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D053843:DNA Mismatch Repair / Q000235:genetics; D004252:DNA Mutational Analysis; D004268:DNA-Binding Proteins / Q000235:genetics*; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D020868:Gene Silencing; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D018714:Radiotherapy, Adjuvant; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D004268:DNA-Binding Proteins; C094443:G-T mismatch-binding protein; D003606:Dacarbazine; D000077204:Temozolomide